• Featured Product
  • KD/KO Validated

PCSK9 Polyclonal antibody

PCSK9 Polyclonal Antibody for IHC, WB, ELISA

Host / Isotype

Rabbit / IgG


human, rat





Cat no : 55206-1-AP


FH3, HCHOLA3, LDLCQ1, NARC 1, NARC1, PC9, PCSK9, Proprotein convertase 9

Tested Applications

Positive WB detected inCOLO 320 cells, rat brain tissue, HepG2 cells, SMMC-7721 cells
Positive IHC detected inhuman colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:3000
Immunohistochemistry (IHC)IHC : 1:250-1:1000
Sample-dependent, check data in validation data gallery

Product Information

55206-1-AP targets PCSK9 in WB, IHC, IF, ELISA applications and shows reactivity with human, rat samples.

Tested Reactivity human, rat
Cited Reactivityhuman, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide
Full Name proprotein convertase subtilisin/kexin type 9
Calculated molecular weight 74 kDa
Observed molecular weight 58-62 kDa, 72-78 kDa
GenBank accession numberNM_174936
Gene symbol PCSK9
Gene ID (NCBI) 255738
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)


Product Specific Protocols
WB protocol for PCSK9 antibody 55206-1-APDownload protocol
IHC protocol for PCSK9 antibody 55206-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols




Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.

Authors - Xinjian Liu
  • KO Validated

Int J Biol Macromol

Purification, structural characterization, and PCSK9 secretion inhibitory effect of the novel alkali-extracted polysaccharide from Cordyceps militaris.

Authors - Jin Wang

Int J Biol Macromol

Purification, characterization and anti-atherosclerotic effects of the polysaccharides from the fruiting body of Cordyceps militaris.

Authors - Xiaoqian Yang
mouseWB, IHC

J Lipid Res

Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein.

Authors - Ya-Qi Wang

J Biol Chem

Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.

Authors - Dandan Wang

Front Mol Biosci

The Cordyceps militaris-Derived Polysaccharide CM1 Alleviates Atherosclerosis in LDLR(-/-) Mice by Improving Hyperlipidemia.

Authors - Fan Yin


The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.


Malak (Verified Customer) (11-30-2020)

The antibody works very well in IHC staining especially at pH6 and 1/100 dilution

  • Applications: Immunohistochemistry
  • Primary Antibody Dilution: 1/100
  • Cell Tissue Type: Hepatic tissue